SAR-7226

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H20F4N2O6
Molecular Weight	436.3548
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C(CC2=C(NN=C2O[C@@H]3O[C@H](CO)[C@@H](F)[C@H](O)[C@H]3O)C(F)(F)F)C=C1

InChI

InChIKey=IBAUCRODUSTJQW-MPZWGZMNSA-N

InChI=1S/C18H20F4N2O6/c1-28-9-4-2-8(3-5-9)6-10-15(18(20,21)22)23-24-16(10)30-17-14(27)13(26)12(19)11(7-25)29-17/h2-5,11-14,17,25-27H,6-7H2,1H3,(H,23,24)/t11-,12-,13+,14-,17+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C18H20F4N2O6
Molecular Weight	436.3548
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:37:14 GMT 2023` Edited by `admin` on `Sat Dec 16 11:37:14 GMT 2023`
Record UNII	9GAQ074U93
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SAR-7226

Common Name

English

.BETA.-D-GLUCOPYRANOSIDE, 4-((4-METHOXYPHENYL)METHYL)-5-(TRIFLUOROMETHYL)-1H-PYRAZOL-3-YL 4-DEOXY-4-FLUORO-

Systematic Name

English

(2S,3R,4R,5S,6R)-5-FLUORO-6-(HYDROXYMETHYL)-2-((4-((4-METHOXYPHENYL)METHYL)-5-(TRIFLUOROMETHYL)-1H-PYRAZOL-3-YL)OXY)TETRAHYDROPYRAN-3,4-DIOL

Systematic Name

English

Code System Code Type Description

FDA UNII

9GAQ074U93

Created by admin on Sat Dec 16 11:37:14 GMT 2023 , Edited by admin on Sat Dec 16 11:37:14 GMT 2023

PRIMARY

PUBCHEM

46213921

Created by admin on Sat Dec 16 11:37:14 GMT 2023 , Edited by admin on Sat Dec 16 11:37:14 GMT 2023

PRIMARY

CAS

702638-25-3

Created by admin on Sat Dec 16 11:37:14 GMT 2023 , Edited by admin on Sat Dec 16 11:37:14 GMT 2023

PRIMARY

Related Record Type Details


					4L3O38V5ZQ

SODIUM/GLUCOSE COTRANSPORTER 1

TARGET -> INHIBITOR


					ZHQ2R96QPT

SODIUM/GLUCOSE COTRANSPORTER 2

TARGET -> INHIBITOR

Related Record Type Details


					9GAQ074U93

SAR-7226

ACTIVE MOIETY

Comments:

Class: Anti-hypoglycaemic; Mechanism of Action: Sodium-glucose transporter 1 inhibitor, Sodium-glucose transporter 2 inhibitor; Highest Development Phase: Discontinued for Type 2 diabetes mellitus. As of Jan 26, 2010 - Sanofi-aventis was developing the dual sodium glucose co-transporter type 1 and type 2 (SGLT1/SGLT2) inhibitor SAR 7226 for the treatment of Type 2 diabetes mellitus.